Vasoxen

Quick links to important sections

Vasoxen

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vasoxen

Quick Facts

Property Description
Active Ingredient Nebivolol (racemic mixture)
Form Oral tablet
Pharmacological Class Beta-adrenergic receptor blocker (Third-generation)
Origin Synthetic
Route Oral administration

Vasoxen: Classification and Identity

Vasoxen is a synthetic, prescription-only medication whose active ingredient is Nebivolol. It is definitively classified as a Beta-adrenergic receptor blocker (beta-blocker), primarily used to modulate the sympathetic activity within the cardiovascular system. Specifically, Nebivolol is recognized as a third-generation beta-blocker, distinguishing itself from older, less-selective agents by demonstrating high selectivity for the cardiac beta1-adrenergic receptor. This unique pharmacological profile is clinically recognized for its potential advantages in a wide variety of hypertensive patients.


Composition, Form, and Origin of Nebivolol

The drug is supplied as a single-ingredient product in an oral tablet formulation, which constitutes its specified route of administration. Chemically, the Nebivolol compound is administered as a racemic mixture of two distinct molecular forms, or stereoisomers. The distinctive profile of this medication is supported by pharmacological properties demonstrating unique vasorelaxant effects, which complement its primary beta-blocking function. These combined effects provide a comprehensive strategy for managing the dynamics of the circulatory system.


General Purpose and Physiological Role

The overall purpose of Vasoxen is to assist in controlling circulatory dynamics by reducing the strain on the heart and enhancing blood vessel function. The core physiological role is achieved by combining the sympatholytic effect—moderating the heart's rate and force—with active promotion of vasodilation in the blood vessels. The active substance, Nebivolol, is primarily indicated for lowering elevated blood pressure. This dual action helps the heart work more efficiently and reduces the force exerted against the artery walls, which is the foundational goal in cardiovascular management.

What side effects are possible with Vasoxen?

Possible Side Effects and Safety Information

The safety profile of Vasoxen (Nebivolol) is based on official regulatory documentation, which organizes potential effects by both frequency and the physiological system affected.

Frequency-Classified Adverse Reactions

The adverse reactions observed in clinical trials are classified into frequency tiers. Common reactions (occurring in 1% to 10% of patients) often involve the Nervous System (e.g., headache, dizziness, paraesthesia) and Gastrointestinal System (e.g., constipation, nausea, diarrhoea). Other common effects include fatigue and oedema.

Uncommon reactions (0.1% to 1% of patients) may involve Cardiac Disorders, such as bradycardia or the aggravation of heart failure, and Psychiatric Disorders, including nightmares and depression.

Very Rare reactions (less than 0.01% of patients) are also documented and include serious events such as angioedema, the aggravation of psoriasis, and severe adverse hepatic reactions.


Population-Specific Safety Constraints

The official label defines specific limitations for use in certain groups. The medicine is contraindicated in individuals with severe hepatic impairment. Furthermore, special caution is required when treating older adults aged over 75 years, and patients with severe renal impairment require specific dosage adjustments. Official regulatory documents list conditions that strictly prohibit the use of the medicine, including acute heart failure and severe bradycardia.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Vasoxen (Nebivolol) is associated with an excessive extension of its primary pharmacological effects, resulting in profound cardiovascular suppression.

Documented Overdose Manifestations

The officially documented clinical signs of an overdose include significant bradycardia (abnormally slow heart rate) and severe hypotension (abnormally low blood pressure). Other manifestations may include dizziness, vomiting, and fatigue. Severe outcomes documented in regulatory sources following large ingestions are cardiac failure, second or third-degree heart block, respiratory failure, and coma. Metabolic changes, such as hypoglycemia (low blood glucose), are also recognized as possible complications.

Emergency Response and Management

In the event of a known or suspected overdose, immediate medical attention must be sought. Official guidance explicitly instructs contacting the National Poison Control Center (1-800-222-1222). No specific antidote is known for Nebivolol; therefore, management is symptomatic and supportive. Regulatory procedures for severe manifestations include administering intravenous atropine for bradycardia, fluids and glucagon for hypotension, and bronchodilator therapy for bronchospasm. Hemodialysis is not expected to enhance the drug's clearance.

Therapeutic Uses of Vasoxen

What Vasoxen Treats: Main Uses and Benefits

Vasoxen is commonly used to help with certain distressing symptoms across two primary therapeutic domains. It is primarily used for the sustained management of essential high blood pressure (hypertension) and the easing of symptoms related to chronic stable angina (chest pain). The medication is applied in clinical settings that involve acute or disruptive symptom patterns and is considered relevant for easing symptoms that interfere with daily comfort.

Quick Fact: Relief for Chest Discomfort

Controlling systemic pressure may assist with maintaining functional stability to support cardiovascular health. Regarding its use for angina, the medication contributes to easing the overall symptom load by helping to decrease the frequency and severity of these symptomatic episodes, assisting with maintaining functional stability during symptomatic periods. It is used in situations involving certain distressing symptoms across therapeutic areas where additional symptomatic support is needed. This supportive action helps improve day-to-day comfort.

Eligibility and Restrictions for Use

Who Can and Cannot Use Vasoxen?

Eligibility for Vasoxen (Nebivolol) is determined by regulatory agencies based on established age groups, underlying cardiac status, and organ function, as documented in official prescribing information.


Contraindicated Populations (Must Not Use)

Use of Vasoxen is contraindicated in patients with a known hypersensitivity to the product or in those with certain high-risk cardiovascular conditions, including:

  • Severe Bradycardia or Heart Block greater than first degree.
  • Cardiogenic Shock or Decompensated Cardiac Failure.
  • Sick Sinus Syndrome (unless a permanent pacemaker is in place).
  • Severe Hepatic Impairment (Child-Pugh Class > B).

Age and Special Population Restrictions

Population Regulatory Status
Pediatric Patients (< 18 yrs) Not recommended; safety and efficacy are not established.
Pregnant Patients Use is conditional; only if the potential benefit justifies the potential risk to the fetus.
Lactating Patients Not recommended due to insufficient data on infant risk.

Organ Function and Disease Cautions

Use is restricted in patients with severe renal impairment or moderate hepatic impairment, often requiring cautious supervision. The medicine must be used with caution in patients with conditions like diabetes mellitus or thyrotoxicosis, as it may mask signs of hypoglycemia or rapid heart rate.

What should I know about interactions with other medicines?

Vasoxen's interaction profile is primarily defined by documented effects on metabolism and cardiovascular activity, as stated in regulatory prescribing information.

Pharmacokinetic Interactions

Vasoxen is metabolized by the CYP2D6 enzyme, and co-administration with CYP2D6 inhibitors such as Fluoxetine, Paroxetine, and Quinidine results in a pharmacokinetic interaction that increases Nebivolol plasma concentrations (increased exposure). This interaction may require dose adjustment according to the FDA label. The gastrointestinal absorption of Nebivolol is inhibited by Aluminum Hydroxide antacids, mandating that the antacid be administered with a timing separation of at least two hours.

Pharmacodynamic Interactions

Substance Category Regulatory Constraint Official Interaction Description
Non-dihydropyridine Calcium Channel Blockers (e.g., Verapamil, Diltiazem) Generally not recommended Additive negative effects on heart rate and contractility, increasing the risk of excessive reduction in heart rate [SmPC].
Class I Antiarrhythmics (e.g., Propafenone, Quinidine) Generally not recommended Potentiation of effect on atrio-ventricular conduction time and increased negative inotropic effect [SmPC].
Centrally-acting Antihypertensives (e.g., Clonidine, Reserpine) Generally not recommended Excessive reduction of sympathetic activity, with a risk of worsening heart failure [SmPC].
Alcohol (Ethanol) Use with caution Produces an additive effect in lowering blood pressure, increasing the risk of hypotension.

Population-Dependent Notes

Individuals classified as CYP2D6 Poor Metabolizers achieve documented significantly higher systemic concentrations of Nebivolol. Additionally, severe renal impairment is associated with decreased renal clearance of the drug, resulting in increased exposure.

Mechanism of Action

Vasoxen's primary mechanism involves the antagonism of beta1-adrenergic receptors predominantly found in the heart, preventing the binding of sympathetic mediators like norepinephrine. This action directly modulates the autonomic signaling pathway responsible for driving heart function, leading to a dose-dependent reduction in the heart's rate and contractile force. This dampening of sympathetic overdrive lowers the myocardial workload and overall cardiac oxygen demand. The drug possesses a unique secondary mechanism by acting as a partial agonist on beta3-adrenergic receptors located on the inner lining (endothelium) of blood vessels. This interaction stimulates the Endothelial Nitric Oxide Synthase (eNOS) enzyme, resulting in the increased production and release of Nitric Oxide (NO). The resulting physiological effect is the relaxation of vascular smooth muscle, which decreases systemic vascular resistance and increases arterial compliance. Vasoxen is a racemic compound where the two stereoisomers work synergistically: one form delivers the cardiac beta1-blockade, and the other drives the NO-mediated vasodilation. This combined action simultaneously reduces cardiac output and peripheral resistance, providing a dual modulation of circulatory dynamics that influences two distinct hemodynamic parameters.

Dosage and Administration Information

Vasoxen (nebivolol) is an oral medication administered as a tablet, typically taken once daily (QD). The tablets are available in official strengths including 2.5 mg, 5 mg, 10 mg, and 20 mg. The medicine may be administered with or without food, but the daily dose should be taken at the same time each day to maintain a consistent schedule.

Official Dosing Regimens and Adjustments

Clinical Scenario Starting Dose and Titration Schedule Maximum Dose
Essential Hypertension 5 mg once daily; the dose is typically increased at 2-week intervals. 40 mg per day
Chronic Heart Failure 1.25 mg once daily; dose is gradually increased. 10 mg per day

Administration Guidelines for Specific Populations

For patients with severe renal impairment or moderate hepatic impairment, the recommended initial dose is 2.5 mg once daily, followed by slow titration if required. Use of the medicine is not recommended for patients with severe hepatic impairment (Child-Pugh Class C). The initiation of therapy for Chronic Heart Failure, as well as subsequent dose increases, requires close supervision by an experienced physician for a minimum of two hours.

If a dose is missed, it should be taken as soon as remembered, unless it is close to the next scheduled dose, in which case the patient must skip the missed dose and not take a double dose. For long-term use, abrupt cessation is avoided; therapy should be gradually tapered over a period of approximately one to two weeks.

Recent Clinical Evidence

Research evidence / Overview of studies for Vasoxen


Evidence for use in Essential High Blood Pressure (Hypertension)

The research base for Vasoxen's use in essential high blood pressure relies primarily on numerous Randomized Controlled Trials (RCTs). These studies were set up to explore the compound compared to an inactive treatment (placebo) as well as to other existing anti-hypertensive medications. Researchers evaluated the compound in adults diagnosed with hypertension, including specific groups like older adults.

The main goal of these trials was to explore SBP and DBP measurements over defined time frames. They also monitored other outcomes related to systemic or functional imbalance, such as changes in the Heart Rate (HR) and certain markers of vascular health. Studies reported patterns of change in measured blood pressure. Some trials reported changes in certain vascular health markers in the observed populations. Research highlights that these changes were measured during the study period.


Evidence for use in Easing Symptoms in Chronic Stable Angina

Research has explored the compound in studies concerning symptoms associated with chronic stable angina (chest pain). The available evidence comes from controlled clinical trials, including RCTs. These studies were specifically designed to assess outcomes related to physical discomfort and changes in a person's functional capacity or activity level.

Studies examined changes in the frequency and intensity of angina episodes as reported by patients. They also monitored measurements of physical tasks, often tracking parameters like total exercise duration during standardized tests. Findings describe patterns observed in the studies regarding how the rate of these episodic symptoms changed over the study intervals. Research provides insight into the short-term changes in exercise capacity. The evidence base for this use has a different scope and volume than that for high blood pressure.


Long-Term Studies and Follow-up

The core regulatory studies for Vasoxen often have follow-up durations that were limited, typically ranging from a few weeks to about six months for the primary efficacy measures. While these intervals provide insight into short-term changes in blood pressure and symptom patterns, it is not yet clear whether the short duration provides adequate data regarding long-term cardiovascular outcomes beyond the trial period.

Therefore, long-term effects are not fully established regarding critical cardiovascular events, such as stroke or heart attack. Data are limited for use over extended periods. Studies help show what has been observed so far, but research provides limited insight into sustained patient outcomes beyond the trial period in the primary research.


Evidence in Specific Patient Populations

Research has explored the use of Vasoxen in certain specific groups. For instance, the compound was evaluated in trials that included a specific population of older adults with hypertension. Furthermore, specific analyses were conducted for certain ethnic/racial groups, such as African American/Black patients, to assess if their response patterns differed from the general population in terms of blood pressure and vascular markers.

However, data for certain groups remain insufficient. For example, there is limited information for long-term outcomes in all special populations. Research describes group patterns, not personal outcomes. Study results reflect the specific conditions under which they were conducted and may not represent every individual.


What is Still Uncertain About the Research Evidence

Scientific literature highlights several areas where research remains incomplete. The evidence quality varies across studies, and some trials, particularly those focusing on complex conditions like microvascular angina, utilized sample sizes that were modest. This can limit the generalizability of the findings.

Additionally, comparative evidence is lacking for some of the newer anti-hypertensive agents or highly specific medical conditions. The evidence highlights what is known—and what is still uncertain—about Vasoxen. Research provides context but not individual predictions.

Key Studies & References Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients (NCT00734630) - Randomized, Double-Blind Study

Frequently Asked Questions (FAQ)

Common questions about Vasoxen (FAQ)


Q: How is Vasoxen different from other common medications for circulation issues?

A: Regulatory documents describe Vasoxen (nebivolol) as a beta-blocker, a type of medicine that primarily affects the heart. Unlike some older beta-blockers, official information highlights that Vasoxen has an additional effect that promotes vasodilation, which is the widening of blood vessels. This dual action on both the heart and blood vessels distinguishes its pharmacological profile.


Q: Does Vasoxen cause drowsiness or tiredness?

A: Official information lists fatigue and dizziness as common side effects that may occur when taking Vasoxen. Some regulatory patient information also mentions that the medicine may make a person feel drowsy or less alert. Official documents describe these effects based on frequency and severity observed in studies. Patient information generally indicates that if these effects occur, individuals should be aware of their own reaction to the medication.


Q: Is Vasoxen a medication that needs to be taken long-term?

A: Vasoxen is approved and indicated for managing conditions like high blood pressure (hypertension) and chronic heart failure, which typically require long-term treatment. Official documents note that if the medicine is discontinued after long-term use, the dose requires gradual reduction over a period of time, as described in the prescribing information.


Q: What information do official sources provide regarding the use of Vasoxen in older adults (seniors)?

A: Official prescribing information confirms that Vasoxen has been evaluated in clinical studies involving older adults for high blood pressure. However, regulatory documents advise special caution when considering treatment for patients over 75 years of age. For certain conditions, such as chronic heart failure, a specific lower initial starting dose is indicated for older adults.


Q: Is Vasoxen available as a generic drug?

A: Yes, the active ingredient in Vasoxen, which is nebivolol, is available as a generic product in various regions. Generic versions are reviewed by regulatory authorities and must meet the same quality standards as the brand-name product.


Q: Is it true that people with liver problems cannot take Vasoxen?

A: The use of Vasoxen is strictly contraindicated (not allowed) for patients who have severe hepatic impairment (severe liver problems). Patients with moderate liver impairment require a specific dosage adjustment and cautious supervision, as described in the official prescribing information.


Q: What is the general safety classification of Vasoxen?

A: Vasoxen is a prescription-only medication that requires a doctor's oversight. Official information indicates that the medicine may cause fetal harm. Therefore, its use is generally restricted during pregnancy and breastfeeding unless conditional use is determined by a healthcare provider.


Q: Why is Vasoxen sometimes described as a vaso-constrictor?

A: The official mechanism of action for Vasoxen describes it as a beta-blocker with a specific secondary action that promotes vasodilation (widening of blood vessels). Regulatory documents do not support describing the drug as a vasoconstrictor, which is a substance that causes the blood vessels to narrow.


Q: Can Vasoxen interact with my over-the-counter pain relievers?

A: Regulatory drug interaction warnings for beta-blockers sometimes note that non-prescription pain relievers known as NSAIDs (e.g., ibuprofen) may reduce the blood pressure-lowering effect. Patient information emphasizes the importance of reviewing all over-the-counter medicines you use with a healthcare provider.


Q: Are there any specific vitamins or supplements that should not be taken with Vasoxen?

A: Regulatory patient safety information routinely advises individuals to inform their doctor or pharmacist about all prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products they take. This is because any of these products may interact with Vasoxen, potentially requiring a dosage adjustment.


Q: How quickly should I expect Vasoxen to start working?

A: Official prescribing information indicates that the maximum blood pressure-lowering effect of Vasoxen is achieved within two to four weeks. For this reason, dosage changes, when needed, are typically evaluated by a physician at intervals of about two weeks.


Q: Does Vasoxen have any restrictions regarding driving or operating machinery?

A: Regulatory information indicates that because side effects like dizziness and fatigue can occur, individuals should be aware of their personal reaction to the medicine before driving a car or operating machinery.


Q: Is Vasoxen known to cause weight gain or weight loss?

A: Official lists of common side effects for Vasoxen do not prominently feature weight changes. However, official patient warnings indicate that rapid or unusual weight change, such as rapid weight gain, may be a sign of fluid retention, a condition which requires clinical assessment.


Q: What is the significance of the research evidence for Vasoxen?

A: Research evidence, as summarized in regulatory documents, provides the basis for the approved use of Vasoxen for specific conditions. These findings indicate the compound's effect on lowering blood pressure and supporting cardiovascular health, establishing the official indications for use.


Q: Do I need any special monitoring (like blood tests) while on Vasoxen?

A: Official regulatory documents emphasize the need for careful monitoring for patients with certain pre-existing conditions. For example, patients with diabetes must be monitored closely, as the medicine may mask some of the signs of low blood sugar (hypoglycemia).


Q: Does Vasoxen have a risk of dependence or addiction?

A: Official patient information in various regions, based on regulatory data, explicitly states that Vasoxen (nebivolol) is not considered addictive or associated with a risk of dependence.


Q: What should I do if I suspect an interaction between Vasoxen and another medicine?

A: Official drug interaction information strongly advises patients to notify their healthcare provider or pharmacist about all other medicines, supplements, or herbal products they take. In the event a patient suspects an interaction, official guidance directs the patient to contact their healthcare provider or pharmacist immediately.


Q: Are there any warnings about using Vasoxen with herbal remedies?

A: Regulatory patient safety information generally advises patients to discuss all herbal products they are taking with their doctor or pharmacist. Herbal remedies, like any other substance, have the potential to interact with Vasoxen.


Q: Does the efficacy of Vasoxen decrease over time?

A: Regulatory documents indicate that Vasoxen is intended for the long-term management of chronic conditions. There is no widespread information in the official drug labels concerning a decrease in efficacy over time for its approved uses.


Q: Is Vasoxen a scheduled or controlled substance?

A: No, Vasoxen is a standard prescription drug. According to regulatory classifications in the U.S., it has no DEA Schedule designation, meaning it is not considered a federally controlled substance.


Q: Does taking Vasoxen require lifestyle changes, like diet or exercise?

A: Regulatory documents state that controlling high blood pressure should be part of a comprehensive cardiovascular risk management plan. This plan includes, as appropriate, complementary measures such as increased exercise and limited sodium intake (dietary changes), in addition to the medicine.


Q: What kind of specialist usually prescribes Vasoxen?

A: Vasoxen is commonly prescribed by general practitioners and cardiologists for its primary indication. However, regulatory documents state that the initial therapy for certain complex conditions, such as Chronic Heart Failure, requires close supervision by an experienced physician.

How should Vasoxen be stored and disposed of?

Vasoxen (Nebivolol) tablets must be stored according to specific instructions to preserve product quality. The official storage temperature is controlled room temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F). The product must be kept in the container it came in, tightly closed, and stored away from excess heat and moisture. The tablets must not be frozen.

Storage Condition Official Requirement
Temperature Controlled Room Temperature (20 C to 25 C)
Protection Avoid excess heat and moisture; Do not freeze
Container Keep in original, tightly closed container
Safety Keep out of the sight and reach of children

For disposal, the preferred option is to use an official drug take-back program. If a program is not available, the unused medicine should be mixed with an undesirable substance (e.g., used coffee grounds, dirt), placed into a sealed container, and thrown into household trash, in accordance with local regulations. Personal information must be removed from the packaging before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vasoxen found in:

A-Z Index: